The coronavirus vaccine, which is being developed by the Federal Biomedical Agency (FMBA), will protect against infection against any mutation, said Tatyana Yakovleva, First Deputy Head of FMBA. FMBA will complete preclinical trials of the drug in June, and clinical trials will begin in July.
According to Ms. Yakovleva, the FMBA vaccine develops not only humoral immunity (it lasts no more than six months) for certain proteins, like existing drugs, but also cellular immunity. “The drug we are working on at FMBA Russia also develops cellular immunity, that is, it targets conservative proteins. Whatever mutation occurs, this vaccine will still protect us from COVID-19, “she said in an interview with Izvestia.
Four vaccines against COVID-19 have been registered in Russia: Sputnik V and Sputnik Light at the Gamaleya Center, EpiVacCorona at the Vector Center and KoviVak at the Chumakov Center. Since the beginning of the pandemic, more than 5 million people infected with COVID-19 have been identified in Russia, 122 thousand people have died.
For more information on the development of the FMBA vaccine, see the article by Kommersant, “Peace in Time of the Plague.”